← Russell 3000 cross-section

EYE National Vision Holdings, Inc.

Trailing twelve months to 2026-07-04 · as filed 2026-08-13, not restated
Healthcare

Scale

Market cap
$1.4bn
Revenue TTM
$2.0bn
Net income TTM
$50m
Free cash flow
$49m
Composite score
54.3
Sector rank
#1821

Valuation

P / E
28.5
EV / EBITDA
EV / sales
0.8
FCF yield
3.43%
Earnings yield vs 10-yr
-1.22pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
2.5%
EBITDA margin
ROE
5.6%
ROIC
7.7%
Revenue growth
7.8%

Insider activity, last 90 days

Net open-market
$0.78m
Buyers
1
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Increases or decreases in deferred revenue during the reporting period represent cash collections in excess of, or below the recognition of, previous deferrals. Less than 10% of our costs applicable to revenue are directly subject to tariffs on products from China. In Mexico, where our exposure relates to our outsourcing relationship with our third-party laboratory, we have mitigation plans in place, and we estimate that less than 1% of our costs applicable to revenue are subject to tariffs in Mexico. …National Vision Holdings, Inc., 10-Q, period ended 2026-07-04, filed 2026-08-13

Read the full passage →